Vanda Pharmaceuticals Inc. 8-K
Research Summary
AI-generated summary
Vanda Pharmaceuticals Inc. Senior VP, General Counsel Resigns
What Happened
Vanda Pharmaceuticals Inc. (VNDA) filed a Form 8-K (Item 5.02) reporting that Timothy Williams notified the company on March 29, 2026 of his resignation as Senior Vice President, General Counsel and Secretary. His resignation is effective April 10, 2026. The 8-K was filed April 2, 2026 and signed by Kevin Moran, Senior VP, Chief Financial Officer and Treasurer.
Key Details
- Filing: Form 8-K (Item 5.02) filed April 2, 2026.
- Resignation notice date: March 29, 2026.
- Effective resignation date: April 10, 2026.
- Position: Senior Vice President, General Counsel and Secretary (Timothy Williams).
- Filing includes no disclosure of a successor or other arrangements.
Why It Matters
An incoming departure of the company’s top legal officer is a governance and operational detail investors monitor because the general counsel handles legal, compliance and corporate governance matters. The 8-K confirms the timing of the change but does not provide information on a replacement or transitional plan; investors may watch subsequent filings or company announcements for details on succession and any potential impacts to regulatory or legal work.